MARKET

FULC

FULC

Fulcrum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.05
-0.08
-0.66%
Opening 11:32 12/02 EST
OPEN
12.13
PREV CLOSE
12.13
HIGH
12.17
LOW
11.76
VOLUME
11.33K
TURNOVER
--
52 WEEK HIGH
22.96
52 WEEK LOW
7.01
MARKET CAP
330.92M
P/E (TTM)
-4.2362
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Here's Why We're Not Too Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 11/16 14:18
Novavax (NVAX) Loss Widens in Q3, Revenues Lag Estimates
Novavax's (NVAX) bottom line deteriorates year over year in the third quarter of 2020. Revenues fall shy of estimates as well. Stock dips in after-hours trading.
Zacks · 11/10 16:30
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) --  Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the Investigational New Drug application (IND) is now in effect
GlobeNewswire · 10/05 12:00
Fulcrum Therapeutics on go with early-stage study with FTX-6058 for sickle cell
The FDA signs off Investigational New Drug application ((IND)) to commence Phase 1 trial for Fulcrum Therapeutics's (FULC) FTX-6058 for sickle cell disease.The trial will evaluate the safety, tolerability and pharmacokinetics of
Seekingalpha · 10/05 11:47
Fulcrum Therapeutics To Initiate Phase 1 Trial With FTX-6058 For Sickle Cell Disease
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) --  Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined
Benzinga · 10/05 11:01
Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced it will present multiple posters on the company’s ongoing studies in patients with facioscapulohumeral muscular dystrophy
GlobeNewswire · 10/01 12:00
Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting
\- Fetal Hemoglobin expression in human cellular models increased up to ~30% by FTX-6058 for the potential treatment of sickle-cell disease \- Company plans to initiate Phase 1 trial in healthy volunteers by year-end\- Non-provisional composition of matter patent application covering FTX
GlobeNewswire · 09/25 19:15
Fulcrum Therapeutics' FTX-6058 shows encouraging action preclinical studies
Fulcrum Therapeutics ([[FULC]] +5.5%) has announced preclinical proof-of-concept data from FTX-6058, for the treatment of sickle cell disease and beta-thalassemia.FTX-6058, a small molecule is designed to increase expression of fetal
Seekingalpha · 09/25 19:08
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FULC. Analyze the recent business situations of Fulcrum through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FULC stock price target is 18.17 with a high estimate of 23.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 72
Institutional Holdings: 19.92M
% Owned: 72.52%
Shares Outstanding: 27.46M
TypeInstitutionsShares
Increased
18
1.52M
New
22
-1.32M
Decreased
11
55.41K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.14%
Pharmaceuticals & Medical Research
+0.55%
Key Executives
Chairman/Independent Director
Mark Levin
President/Chief Executive Officer/Director/Primary Contact
Robert Gould
Chief Operating Officer
Bryan Stuart
Senior Vice President
Diego Cadavid
Chief Scientific Officer
Owen Wallace
Independent Director
James Collins
Independent Director
Katina Dorton
Independent Director
Alan Ezekowitz
Independent Director
James Geraghty
Independent Director
james Geraghty
Independent Director
Kate Haviland
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About FULC
Fulcrum Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Fulcrum Therapeutics Inc stock information, including NASDAQ:FULC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FULC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FULC stock methods without spending real money on the virtual paper trading platform.